Successful treatment of an anti-MDA5 antibody-positive Juvenile Dermatomyositis patient with refractory interstitial lung disease using tofacitinib

Pediatr Rheumatol Online J. 2025 Feb 25;23(1):22. doi: 10.1186/s12969-024-01044-5.

Valentina Natoli^{1

2}, Serena Palmeri¹, Ana Isabel Rebollo-Giménez^{1

3}, Caterina Matucci-Cerinic^{1

2}, Paola Bocca², Roberta Caorsi², Stefano Volpi^{1

2}, Riccardo Papa², Alessandro Consolaro^{1

2}, Marco Gattorno², Angelo Ravelli^{1

4}, Silvia Rosina⁵

¹ Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy.
² IRCCS Istituto Giannina Gaslini, Paediatric Rheumatology and Autoinflammatory Diseases Unit, Genoa, Italy.
³ Hospital Universitario Príncipe de Asturias, Madrid, Spain.
⁴ IRCCS Istituto Giannina Gaslini, Direzione Scientifica, Genoa, Italy.
⁵ IRCCS Istituto Giannina Gaslini, Paediatric Rheumatology and Autoinflammatory Diseases Unit, Genoa, Italy. silviarosina@gaslini.org.

No abstract available

Keywords: Anti-MDA5 antibodies; Interstitial lung disease; JAK inhibitors; Juvenile dermatomyositis; Tofacitinib; Type I IFN gene signature.

Publication types